Investment Analysts’ Recent Ratings Updates for Alexion Pharmaceuticals (ALXN)

A number of research firms have changed their ratings and price targets for Alexion Pharmaceuticals (NASDAQ: ALXN):

  • 2/9/2018 – Alexion Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $177.00 to $180.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $151.00 price target on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $148.00 to $151.00. They now have an “overweight” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target lowered by analysts at Leerink Swann from $166.00 to $153.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals was given a new $161.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target lowered by analysts at Citigroup Inc from $173.00 to $170.00. They now have a “buy” rating on the stock.
  • 2/5/2018 – Alexion Pharmaceuticals was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating.
  • 2/2/2018 – Alexion Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/18/2018 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $147.00 price target on the stock.
  • 1/4/2018 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $130.00 price target on the stock, down previously from $178.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/4/2018 – Alexion Pharmaceuticals was downgraded by analysts at UBS Group AG from a “strong-buy” rating to an “outperform” rating.
  • 12/27/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/18/2017 – Alexion Pharmaceuticals was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $150.00 price target on the stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $108.60 on Monday. The company has a market capitalization of $24,074.60, a P/E ratio of 55.41, a PEG ratio of 0.95 and a beta of 1.16. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.25 earnings per share for the current year.

In other news, EVP John B. Moriarty sold 3,363 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now owns 71,400 shares in the company, valued at approximately $8,260,980. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the transaction, the senior vice president now owns 47,212 shares of the company’s stock, valued at approximately $5,491,227.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,930 shares of company stock valued at $3,378,199. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply